Story at a Glance:
•Natural light is an essential nutrient many of us lack within our bodies. When ultraviolet light is introduced into the bloodstream, remarkable health benefits emerge.
• Once ultraviolet blood irradiation (UVBI) was discovered in the 1930s, it produced miraculous results for patients on the verge of death and was quickly adopted by hospitals throughout America, demonstrating remarkable efficacy for a wide range of diseases.
• To neutralize this competition, the American Medical Association published a doctored study that “debunked” UVBI, and it became a forgotten therapy. Russians and Germans recognized its value and have produced decades of research showing UVBI’s remarkable utility.
• This article explores UVBI’s remarkable history, systematic suppression, and scientific foundation, demonstrating why this therapy represents one of medicine’s lost opportunities.
I have attempted to make the case that we are routinely denied vital knowledge, treatment, and care to protect the interests of the medical industrial complex. For example:
• I’ve highlighted how unsafe pharmaceuticals make it to market because approval panels
German and Russian researchers developed alternative approaches—directly applying a laser onto surface blood vessels (e.g., behind the knee or under the tongue) or threading fiber optic cables into vessels and illuminating from inside. These approaches (collectively known as laser blood irradiation or LBI) have been found relatively equivalent, with LBI requiring more treatments.
A leading researcher determined LBI had more rapid effects and was better for bronchodilation and allergen hyposensitization, while UBI had more substantial bactericidal and anti-inflammatory effects. Two weeks after treatment, UBI typically obtained better microcirculation results than LBI.
Numerous studies demonstrate that LBI is effective for a wide range of medical conditions, with varying effects depending on the light wavelengths used. To quote a recent review paper about LBI use in Russia:
Additionally:
• Unlike UVBI, LBI is not easily obtainable in the United States.
• Unlike UVBI, LBI can only apply one wavelength at a time (due to laser coherence needs).
UVBI Research Foundation
UVBI researchers have identified over 200 journal articles on UVBI and LBI published between 1934 and 2020, with a third viewable online. These studies consistently found a complete absence of side effects from UVBI.
Conditions with evidence of UVBI efficacy include:
• Bacterial Infections (sepsis, septic abortions, osteomyelitis, meningitis, tuberculosis, typhoid fever)
• Viral Infections (pneumonia, shingles, hepatitis, severe COVID-19, long COVID, polio, AIDS)
• Cardiovascular Disorders (heart attacks, angina, peripheral arterial disease, intermittent claudication, Raynaud’s, thrombophlebitis, high blood pressure, pulmonary hypertension)
• Autoimmune disorders (rheumatoid arthritis, asthma, eczema, multiple sclerosis, transplant rejections). For example, one reader recently shared with me after learning about UVBI she started in and cured 20 years of Crohn’s disease (bowel inflammation).
• Abdominal Conditions (liver, biliary and gallbladder diseases, pancreatitis, disseminated peritonitis, kidney diseases)
• Surgery (preventing post-operative complications, reducing death rates, accelerating recovery, treating postoperative ileus or burns)
• Obstetrics and Gynecology (male and female fertility, preventing miscarriages, preeclampsia, healthy babies, polycystic ovarian syndrome, pelvic inflammatory diseases)
• Neurologic and Psychiatric Disorders (depression, schizophrenia, migraine headaches, poor cerebral blood flow creating tinnitus, foggy head or insomnia)
Note: all of the studies for the above conditions are discussed and summarized in this article.
Vasogen: The Patent Solution
One major UVBI barrier is that it’s not patentable and cannot justify the immense costs of clinical trials and lobbying for FDA approval. In the 1990s, the Canadian company Vasogen attempted to solve this problem by creating a device that mixed ozone, UVBI, and heat within its proprietary device, then injected it into the gluteal muscle.
This proprietary approach (deemed “irrational” by a leading ozone researcher) performed significantly worse than other methods but still produced remarkable results, resulting in Vasogen raising 225 million dollars, conducting over 60 studies over 8 years, demonstrating safety, securing over 24 patents, and publishing a successful Phase II trial for chronic heart failure and peripheral vascular disease.
Unfortunately, due to a poorly designed Phase III trial (which had benefits but failed to achieve statistical significance), Vasogen went bankrupt. Few now know the company existed or that costly required Phase I and Phase II studies for UVBI have already been done.
Additionally, in 2015, AVIcure Bioscience published a Phase II safety study for UVBI, and in 2019, it published a successful Phase III clinical trial. Both trials showed safety for all patients and efficacy for the majority. Unfortunately, these studies on hepatitis C were conducted, and simultaneously, effective pharmaceutical treatments for hepatitis C hit the market, eliminating interest in alternative approaches.
Remarkably, despite all this evidence and widespread usage for nearly a century, UVBI is still called “fringe” or “pseudoscientific” therapy with “no evidence,” illustrating why those terms are meaningless.
Note: the key requirement of the 2018 Right to Try Act is that Phase I safety studies have been completed.
Conclusion
The UVBI story represents a forgotten side of medicine—a safe, effective, affordable therapy that could have saved millions of lives was systematically buried to protect pharmaceutical profits. Despite overwhelming evidence from hundreds of studies and thousands of successfully treated patients over nearly a century, UVBI remains marginalized in American medicine.
The pattern—initial enthusiasm, remarkable results, systematic suppression through fraudulent studies, eventual marginalization—has been repeated with countless promising therapies. From hydroxychloroquine and ivermectin during COVID-19 to IV vitamin C for sepsis, the medical establishment consistently employs the same playbook to eliminate competition to expensive pharmaceutical interventions.
Yet UVBI persists, quietly helping patients in integrative medicine practices across America and openly studied in countries like Russia and Germany. The therapy Dr. George Miley called “one of the greatest contributions to medicine ever made by a citizen of the United States” continues demonstrating remarkable potential for those fortunate enough to access it.
Understanding this history reveals fundamental corruption within our medical system—a system that prioritizes profits over patients and consistently suppresses safe, effective treatments that threaten pharmaceutical revenues. Only by recognizing these patterns can we begin to reclaim the remarkable healing potential that has been stolen from us.
Author’s note: This is an abridged version of a longer article about UVBI which goes into greater detail on the mechanisms behind UVBI, summarizes its vast body of published literature, and provides resources for those interested in accessing the most effective forms of this therapy (something many have now reported benefitting from). That article and its additional references can be read here.
